153 related articles for article (PubMed ID: 35741835)
21. A novel ferroptosis-related gene signature associated with cell cycle for prognosis prediction in patients with clear cell renal cell carcinoma.
Chen S; Zhang E; Guo T; Shao J; Wang T; Zhang N; Wang X; Zheng J
BMC Cancer; 2022 Jan; 22(1):1. PubMed ID: 34979993
[TBL] [Abstract][Full Text] [Related]
22. Cancer-associated fibroblasts impact the clinical outcome and treatment response in colorectal cancer via immune system modulation: a comprehensive genome-wide analysis.
Chen YF; Yu ZL; Lv MY; Cai ZR; Zou YF; Lan P; Wu XJ; Gao F
Mol Med; 2021 Oct; 27(1):139. PubMed ID: 34717544
[TBL] [Abstract][Full Text] [Related]
23. Key Molecules in Bladder Cancer Affect Patient Prognosis and Immunotherapy Efficacy: Further Exploration for
Zhou T; Chen H; Wang Y; Wen S; Dao P; Chen M
JCO Precis Oncol; 2023 Jul; 7():e2200630. PubMed ID: 37437228
[TBL] [Abstract][Full Text] [Related]
24. Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer.
Gui CP; Li JY; Fu LM; Luo CG; Zhang C; Tang YM; Zhang LZ; Shu GN; Wu RP; Luo JH
J Big Data; 2022; 9(1):88. PubMed ID: 35818395
[TBL] [Abstract][Full Text] [Related]
25. Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer.
Wang Y; Chen L; Yu M; Fang Y; Qian K; Wang G; Ju L; Xiao Y; Wang X
Cancer Med; 2020 Oct; 9(20):7729-7741. PubMed ID: 32841548
[TBL] [Abstract][Full Text] [Related]
26. Systematical analysis of ferroptosis regulators and identification of GCLM as a tumor promotor and immunological biomarker in bladder cancer.
Wang S; Wang H; Zhu S; Li F
Front Oncol; 2022; 12():1040892. PubMed ID: 36353567
[TBL] [Abstract][Full Text] [Related]
27. A novel ferroptosis-related gene prognostic index for prognosis and response to immunotherapy in patients with prostate cancer.
Wang Y; Fan J; Chen T; Xu L; Liu P; Xiao L; Wu T; Zhou Q; Zheng Q; Liu C; Chan FL; Wu D
Front Endocrinol (Lausanne); 2022; 13():975623. PubMed ID: 36034466
[TBL] [Abstract][Full Text] [Related]
28. Development of a Ferroptosis-Related lncRNA Signature to Predict the Prognosis and Immune Landscape of Bladder Cancer.
Zhou R; Liang J; Tian H; Chen Q; Yang C; Liu C
Dis Markers; 2021; 2021():1031906. PubMed ID: 34239619
[TBL] [Abstract][Full Text] [Related]
29. Machine learning identifies the role of SMAD6 in the prognosis and drug susceptibility in bladder cancer.
Chen Z; Ou Y; Ye F; Li W; Jiang H; Liu S
J Cancer Res Clin Oncol; 2024 May; 150(5):264. PubMed ID: 38767747
[TBL] [Abstract][Full Text] [Related]
30. Identification of Prognosis-Related Genes in Bladder Cancer Microenvironment across TCGA Database.
Zhao X; Tang Y; Ren H; Lei Y
Biomed Res Int; 2020; 2020():9143695. PubMed ID: 33204728
[TBL] [Abstract][Full Text] [Related]
31. The feasibility of proteomics sequencing based immune-related prognostic signature for predicting clinical outcomes of bladder cancer patients.
Jiang L; Chen S; Pan Q; Zheng J; He J; Sun J; Han Y; Yang J; Zhang N; Fu G; Gao F
BMC Cancer; 2022 Jun; 22(1):676. PubMed ID: 35725413
[TBL] [Abstract][Full Text] [Related]
32. Ferroptosis-related gene signature predicts prognosis and immunotherapy in glioma.
Wan RJ; Peng W; Xia QX; Zhou HH; Mao XY
CNS Neurosci Ther; 2021 Aug; 27(8):973-986. PubMed ID: 33969928
[TBL] [Abstract][Full Text] [Related]
33. Integrated Analysis Revealed an Inflammatory Cancer-Associated Fibroblast-Based Subtypes with Promising Implications in Predicting the Prognosis and Immunotherapeutic Response of Bladder Cancer Patients.
Chen H; Yang W; Xue X; Li Y; Jin Z; Ji Z
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555612
[TBL] [Abstract][Full Text] [Related]
34. Crosstalk between Mesenchymal Stem Cells and Cancer Stem Cells Reveals a Novel Stemness-Related Signature to Predict Prognosis and Immunotherapy Responses for Bladder Cancer Patients.
Ma L; Chen H; Yang W; Ji Z
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902193
[TBL] [Abstract][Full Text] [Related]
35. Ferroptosis and cuproptosis prognostic signature for prediction of prognosis, immunotherapy and drug sensitivity in hepatocellular carcinoma: development and validation based on TCGA and ICGC databases.
Ma Q; Hui Y; Huang BR; Yang BF; Li JX; Fan TT; Gao XC; Ma DY; Chen WF; Pei ZX
Transl Cancer Res; 2023 Jan; 12(1):46-64. PubMed ID: 36760376
[TBL] [Abstract][Full Text] [Related]
36. Construction of a ferroptosis-related five-lncRNA signature for predicting prognosis and immune response in thyroid carcinoma.
Qin Y; Zhang D; Zhang H; Hou L; Wang Z; Yang L; Zhang M; Zhao G; Yao Q; Ling R; Zhang J
Cancer Cell Int; 2022 Sep; 22(1):296. PubMed ID: 36175889
[TBL] [Abstract][Full Text] [Related]
37. A circadian rhythm-related gene signature associated with tumor immunity, cisplatin efficacy, and prognosis in bladder cancer.
Zhou R; Chen X; Liang J; Chen Q; Tian H; Yang C; Liu C
Aging (Albany NY); 2021 Dec; 13(23):25153-25179. PubMed ID: 34862329
[TBL] [Abstract][Full Text] [Related]
38. Tertiary lymphoid structure patterns aid in identification of tumor microenvironment infiltration and selection of therapeutic agents in bladder cancer.
An Y; Sun JX; Xu MY; Xu JZ; Ma SY; Liu CQ; Liu Z; Wang SG; Xia QD
Front Immunol; 2022; 13():1049884. PubMed ID: 36420257
[TBL] [Abstract][Full Text] [Related]
39. Prognostic and therapeutic significance of a novel ferroptosis related signature in colorectal cancer patients.
Du S; Zeng F; Sun H; Liu Y; Han P; Zhang B; Xue W; Deng G; Yin M; Cui B
Bioengineered; 2022 Feb; 13(2):2498-2512. PubMed ID: 35067161
[TBL] [Abstract][Full Text] [Related]
40. Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma.
Wang Y; Chen L; Ju L; Xiao Y; Wang X
Int Immunopharmacol; 2020 Oct; 87():106818. PubMed ID: 32738594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
